您好，欢迎来到试剂仪器网！ [登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > Parathyroid hormone(1-34)(human)
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Parathyroid hormone(1-34)(human)
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Parathyroid hormone(1-34)(human)图片
CAS NO:52232-67-4
包装与价格：
包装价格(元)
1mg电议
5mg电议
10mg电议
25mg电议

产品介绍

化学性质

Physical AppearanceA solid
StorageDesiccate at -20°C
M.Wt4117.75
Cas No.52232-67-4
FormulaC181H291N55O51S2
SynonymsSer-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe
Solubility≥399.3 mg/mL in DMSO; insoluble in EtOH; ≥19.88 mg/mL in H2O
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

Parathyroid hormone (1-34) (human),(C181H291N55O51S2),是序列为H2N-SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF-OH的多肽,分子量为4117.72.甲状旁腺激素(PTH)是由甲状旁腺主细胞分泌的含有84个氨基酸的多肽.它的作用是增加血液中钙离子(Ca2+)的浓度,而降钙素(由甲状腺的滤泡旁细胞(C细胞)产生的激素)的作用是降低钙离子浓度.PTH通过作用于甲状旁腺激素受体1和甲状旁腺激素受体2来增加血液中钙离子的浓度(1).甲状旁腺激素可以提高骨骼大型储存库中的钙离子释放,调节血清钙(2).它促进钙\镁离子经远端小管和髓袢升支粗段的主动重吸收(3).它通过增加活性维生素D的生成来促进肠道中钙离子的吸收.

参考文献:
1.Bieglmayer C, Prager G, Niederle B (October 2002). "Kinetic analyses of parathyroid hormone clearance as measured by three rapid immunoassays during parathyroidectomy". Clin. Chem. 48 (10): 1731–8.
2.PooleK, Reeve J (2005). "Parathyroid hormone - a bone anabolic and catabolic agent". Curr Opin Pharmacol 5 (6): 612–7.
3.Coetzee M, Kruger MC (May 2004). "Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment?". South. Med. J. 97 (5): 506–11.

试验操作

Cell experiment:[1]

Cell lines

Human kidney 293 cells stably transfected with the human parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor

Reaction Conditions

0 ~ 1000 nM

Applications

PTH (1-34) bound to the PTH/PTHrP receptor with an IC50 value of 2 nM. Moreover, PTH (1-34) stimulated inositol phosphate synthesis (≥ 24 nM) and cAMP production (IC50 = 0.22 nM) in 293 cells stably transfected with the PTH/PTHrP receptor.

Animal experiment:[1]

Animal models

Male Fisher 344 rats, 4 weeks old

Dosage form

10 or 40 μg/kg/day

Once daily by subcutaneous route for 1, 2, or 4 weeks

Applications

Trabecular and cortical bone mass showed a dose- and time-dependent increase in the treated animals compared with the controls. These increases were evident as early as 1 week after initiation of dosing.

Note

The technical data provided above is for reference only.

References:

1. Frolik CA, Cain RL, Sato M, et al. Comparison of recombinant human PTH(1-34) (LY333334) with a C-terminally substituted analog of human PTH-related protein(1-34) (RS-66271): In vitro activity and in vivo pharmacological effects in rats. Journal of Bone and Mineral Research, 1999, 14(2): 163-172.